Condition
Hypersensitivity Reaction
Total Trials
4
Recruiting
0
Active
0
Completed
2
Success Rate
66.7%-20% vs avg
Key Insights
Highlights
Success Rate
67% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 77/100
Termination Rate
25.0%
1 terminated out of 4 trials
Success Rate
66.7%
-19.8% vs benchmark
Late-Stage Pipeline
25%
1 trials in Phase 3/4
Results Transparency
0%
0 of 2 completed with results
Key Signals
67% success
Data Visualizations
Phase Distribution
4Total
Not Applicable (2)
P 1 (1)
P 3 (1)
Trial Status
Completed2
Not Yet Recruiting1
Terminated1
Trial Success Rate
66.7%
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT07268248Not ApplicableNot Yet Recruiting
1-hour Premedication for Allergy Goal in Emergency: PAGE-1 Study
NCT02349763Phase 3CompletedPrimary
Dexamethasone Regimens for Prophylaxis of Paclitaxel-associated Hypersensitivity Reaction
NCT04035707Not ApplicableCompletedPrimary
Serum Tryptase Concentration During General Anaesthesia With Rocuronium
NCT02185651Phase 1Terminated
A Pilot Study of Zavesca® in Patients With Pompe Disease and Infusion Associated Reaction
Showing all 4 trials